Cytomedix, Inc. is a biotechnology company developing advanced tissue regeneration technologies. Our primary focus is on commercializing autologous cell based therapies that facilitate the body’s natural healing processes for enhanced healing and tissue repair. Our commercial portfolio is based on autologous platelet rich plasma (“PRP”) platform technology, and includes the Angel® Whole Blood Separation System (“Angel®”) and the AutoloGelTM System (“AutoloGel”).
The AutoloGel™ System launched in 2008 after receiving marketing clearance (510K) from the FDA for exuding wounds. The success of AutoloGel™ PRP is based on a proprietary formulation which utilizes a complex cocktail of proteins, cytokines, and growth factors derived from autologous plasma and platelets. Autologel™ System
Cytomedix' evolution into a broad-based regenerative medicine company began with the 2010 acquisition of the best-in-class PRP platform technology: the Angel PRP System. Angel® System
In February 2012, we acquired Aldagen, a clinical-stage biopharmaceutical company developing regenerative cell therapies based on proprietary a novel, patent-protected cell selection technology. Pipeline